This is a working overview of c-Met, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-26 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
== Background == By the mid-1790s, Humboldt had devoted himself wholly to scientific investigations. Despite being offered a promotion and an increase in pay, he resigned his position as a mining official in the Prussian civil service in order to embark on a journey that would “advance him scientifically.” To the Minister of Mines in Berlin Humboldt declared: "I am considering a complete change in my mode of life, and I intend to withdraw from any official position with the state." His health, he claimed, had suffered. All he had wanted was to prepare himself for a scientific expedition by a practical employment in the mines. "As I have a deep conviction that such an expedition is highly important for increasing our knowledge of geology and physical science, I am exceedingly eager to devote my energies immediately to this end. After his mother's death in 1796, Humboldt inherited the financial means to pursue independent explorations. He decided to go to Italy, where he wanted to spend a year to a year and a half researching volcanoes. From there, he wanted to travel via Paris to England, where he would board a ship to the West Indies. However, the political instability caused by Napoleon's Italian campaign in 1797 forced Humboldt to cancel his plans. In May 1798, Humboldt traveled to Paris, where he met the botanist Aimé Bonpland. After their attempt to travel to Egypt had once again failed due to Napoleon and his campaign there, the two decided to go to Madrid in December 1798.
The initial contact between macrophage antigen-bound MHC II and TCR serves as the contact point between the two cells where most of the IFN-γ secretion and CD-40L on T cells concentrate to, so only macrophages directly interacting with TH1 cells are likely to be activated. In addition to activating M1 macrophages, TH1 cells express Fas ligand (FasL) and lymphotoxin beta (LT-β) to help kill chronically infected macrophages that can no longer kill pathogens. The killing of chronically infected macrophages release pathogens to the extracellular space that can then be killed by other activated macrophages. TH1 cells also help recruit more monocytes, the precursor to macrophages, to the infection site. TH1 secretion TNF-α and LT-α to make blood vessels easier for monocytes to bind to and exit. TH1 secretion of CCL2 as a chemoattractant for monocytes. IL-3 and GM-CSF released by TH1 cells stimulate more monocyte production in the bone marrow. When intracellular pathogens cannot be eliminated, such as in the case of Mycobacterium tuberculosis, the pathogen is contained through the formation of granuloma, an aggregation of infected macrophages surrounded by activated T cells. The macrophages bordering the activated lymphocytes often fuse to form multinucleated giant cells that appear to have increased antimicrobial ability due to their proximity to TH1 cells, but over time, the cells in the center start to die and form necrotic tissue.
Guanidine is the compound with the formula HNC(NH2)2. It is a colourless solid that dissolves in polar solvents. It is a strong base that is used in the production of plastics and explosives. It is found in urine predominantly in patients experiencing renal failure. A guanidine moiety also appears in larger organic molecules, including on the side chain of arginine.
Butane-1,4-diol is also used as a recreational drug known by some users as "Bute", "One Comma Four", "Liquid Fantasy", "One Four Bee" or "One Four B-D-O". Some federal courts in the United States have stated that 1,4-butanediol exerts effects similar to its metabolite, GABA analogue gamma-hydroxybutyrate (GHB), but several other federal courts have ruled that it does not. 1,4-butenediol (CAS 110-64-5) may be incorrectly sold as 1,4-butanediol but should not be confused with it.
Sources: en.wikipedia.org
Amphetamine, discovered before methamphetamine, was first synthesized in 1887 in Germany by Romanian chemist Lazăr Edeleanu who named it phenylisopropylamine. Shortly after, methamphetamine was synthesized from ephedrine in 1893 by Japanese chemist Nagai Nagayoshi. Three decades later, in 1919, methamphetamine hydrochloride was synthesized by pharmacologist Akira Ogata via reduction of ephedrine using red phosphorus and iodine. From 1938, methamphetamine was marketed on a large scale in Germany as a nonprescription drug under the brand name Pervitin, produced by the Berlin-based Temmler pharmaceutical company. It was used by all branches of the combined armed forces of the Third Reich, for its stimulant effects and to induce extended wakefulness. Pervitin became colloquially known among the German troops as "Stuka-Tablets" (Stuka-Tabletten) and "Herman-Göring-Pills" (Hermann-Göring-Pillen), as a snide allusion to Göring's widely-known addiction to drugs. However, the side effects, particularly the withdrawal symptoms, were so serious that the army sharply cut back its usage in 1940. By 1941, usage was restricted to a doctor's prescription, and the military tightly controlled its distribution. Soldiers would only receive a couple of tablets at a time, and were discouraged from using them in combat. Historian Łukasz Kamieński says,
21 July to 21 September Operation Strangle was conducted by the U.S. 1st Infantry Division and the ARVN 8th Regiment, 5th Division in Bình Dương Province. The operation resulted in 365 PAVN/VC killed and 35 captured.
The National Dope Testing Laboratory (NDTL) is a premier analytical testing & research organization established as an autonomous body under the Ministry of Youth Affairs and Sports, Government of India. It is the only laboratory in the country responsible for human sports dope testing. It is headed by Chief Executive Officer (CEO). Dr. Puran Lal Sahu is the Scientific Director of NDTL. It is accredited by National Accreditation Board for Testing & Calibration Laboratories, NABL (ISO/IEC 17025:2017) for human dope testing of urine & blood samples from human sports. NDTL is one of the 29 WADA accredited laboratories Archived 2021-04-18 at the Wayback Machine in the world. It is one of the modern and state-of-the-art laboratories in the country equipped with the latest analytical instrumentation.
BRD-6929 is a selective inhibitor of HDAC1 and HDAC2, with IC50Tooltip half-maximal inhibitory concentration values of 1 nM and 8–30 nM, respectively, and with 30- to 400-fold selectivity over HDAC3 (IC50 = 398–458 nM) and no inhibition of HDAC8 or class II HDACs (IC50 = >30,000 nM). However, although originally reported to be selective for inhibition of HDAC1 and HDAC2 over HDAC3, subsequent research has found that BRD-6929 is not in fact selective over HDAC3, with previous findings being claimed to have been an assay artifact. As a result, BRD-6929 is no longer recommended as a selective HDAC1 and HDAC2 inhibitor. The drug shows slow-on/slow-off binding kinetics and hence more sustained HDAC inhibition, unlike other HDAC inhibitors like the fast-on/fast-off vorinostat (SAHA) and entinostat (MS-275). Aside from the HDACs, it also showed no binding at 80 other targets at a concentration of 10,000 nM. BRD-6929 produces antidepressant-like and mood-stabilizing-like effects in rodents. This included reducing immobility in the forced swim test (FST) and attenuating amphetamine-induced hyperlocomotion without affecting basal locomotor activity. Conversely, vorinostat was ineffective in these tests. In addition, vorinostat showed dissimilar and lesser effects on gene transcription compared to BRD-6929. These differences may be related to selectivity and duration of exposure, with sustained exposure as with BRD-6929 possibly being advantageous.
The last eukaryotic common ancestor (LECA) is the hypothetical most recent common ancestor of all living eukaryotes – organisms whose cells have a nucleus, around 2 billion years ago. The process by which the LECA came into being, eukaryogenesis, is not understood in detail, but is thought to have involved symbiogenesis, the coming together of an archaean and a bacterium which formed the cell's mitochondria. The LECA's structure and function have been reconstructed by comparing the genomes of modern eukaryotes. This has led biologists to propose that the LECA was a complex cell with a nucleus with a nucleolus and eu/heterochromatin, an endoplasmic reticulum, peroxisomes, endo- and lysosomes, the ESCRT system, a Golgi apparatus, actin-based endo- and exocytosis, pseudopodia or filopodia, sterol-based membranes, G3P + ester bond phospholipids, a microtubule-based cytoskeleton with an organising centre, basal bodies, vacuoles, iron-sulphur cluster biosynthesis via the CIA system, mitochondria, and microtubule-based flagella.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.